Approval · Notice of Compliance 38407 · 2026
NRA-DULOXETINE: Notice of Compliance 38407
Issued October 5, 2026
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 38407
- Date
- October 5, 2026
- Company
- Nora Pharma Inc.Varennes, Quebec, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- Supplement to an Abbreviated New Drug Submission (SANDS), supplement
- Submission class
- Admin
- Reason
- Administrative: Update to labelling (to match Licensor)
- Canadian reference product
- CYMBALTA (Eli Lilly Canada Inc)
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| NRA-DULOXETINE | Not yet assigned | — |
Medicinal ingredients
- DULOXETINE HYDROCHLORIDE 30 MG per CAP
- DULOXETINE HYDROCHLORIDE 60 MG per CAP